Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AR 12

Last Updated: 03/28/17

Status: Determined Ineffective for NF2


  • Treatment Information
  • Additional Information

Arno Therapeutics', AR12 and AR42 were treatment consideration for NF2. Following Phase 0 mice trials, AR42 was determined to be more likely to be effective. AR12 did not go further in clinical trials.

Treatment Information

Other Names
Pharmaceutical Company Arno Therapeutics
Prescription Information Arno Therapeutics - Drug Description
Expectation Change in Meningioma and Schwannoma in CNS

Inhibitor HDAC - Histone deacetylase inhibitors (HDACi), pan-HDAC inhibitor
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021